Selective CDK Inhibitors Using Cysteine-Targeted Covalent Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies face challenges in developing selective inhibitors for cyclin-dependent kinases (CDKs) such as CDK7, CDK12, and CDK13 due to their high sequence and structural similarities, hindering the dissection of their individual contributions to transcription and therapeutic potential in diseases like cancer and inflammatory conditions.
Innovation Solution
Development of compounds that selectively inhibit CDK7, CDK12, and CDK13 by covalently modifying a specific cysteine residue, such as Cys312 of CDK7, Cys1039 of CDK12, and Cys1017 of CDK13, thereby regulating their activities and providing therapeutic options for proliferative and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional inhibitors are used to target CDK7, CDK12, and CDK13, then kinase activity is inhibited, but selectivity is lost due to high sequence and structural similarities among these kinases
Solution Approach 1:
The patent applies local quality by designing inhibitors that specifically target unique local features of CDK7, CDK12, and CDK13 kinases. The compounds are engineered to recognize and bind to distinctive amino acid sequences or structural motifs present in these specific kinases, allowing selective inhibition despite overall structural similarity across the CDK family. This localized targeting approach enables differentiation between closely related kinase targets.
Solution Approach 2:
The patent employs parameter changes by modifying chemical and physical properties of the inhibitor molecules to achieve selective binding. By adjusting parameters such as molecular size, charge distribution, hydrophobicity, and functional group configuration, the compounds are optimized to match the specific binding pocket characteristics of CDK7, CDK12, or CDK13, thereby achieving selectivity through parameter optimization rather than relying solely on sequence differences.
2Measurement precision
If selective inhibitors targeting specific cysteine residues are developed, then individual kinase contributions can be dissected, but development complexity increases
Solution Approach 1:
The patent applies the extraction principle by focusing on and isolating the specific cysteine residue (Cys312 in CDK7, Cys1039 in CDK12, Cys1017 in CDK13) as the unique binding target. Rather than attempting to inhibit the entire kinase domain, the design extracts and targets this specific amino acid residue, which serves as a distinctive handle for selective inhibition. This approach simplifies the design challenge by concentrating on a single critical interaction point rather than the entire complex kinase structure.
Solution Approach 2:
The patent uses the cysteine residue as an intermediary binding site between the inhibitor and the kinase. The sulfur atom in the cysteine thiol group serves as a mediating element that facilitates specific covalent or non-covalent interactions with the inhibitor, enabling selective targeting. This intermediary approach allows the inhibitor to distinguish between CDK7, CDK12, and CDK13 by exploiting subtle differences in the cysteine microenvironment and surrounding residues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit the activity of CDK7, CDK12, and CDK13, offering potential therapeutic benefits in treating cancers, benign neoplasms, angiogenesis-related diseases, inflammatory diseases, and autoimmune diseases by selectively targeting these kinases, thus modulating transcription and cell cycle progression.
Implementation Method 1
compounds that selectively inhibit CDK7, CDK12, and CDK13 by covalently modifying a specific cysteine residue
Data Source
AI summary
The present invention provides novel compounds of Formula (I), (II), or (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK7, CDK12, or CDK13), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.